AI-generated research brief — verify at source
Nonfasting Before Cath Lab Procedures Shows No Worse Safety Outcomes Than Fasting
A meta-analysis of eight randomized controlled trials found no statistically significant differences between fasting and nonfasting patients across five key safety outcomes — including aspiration pneumonia, hypoglycemia, and mortality — before catheterization laboratory procedures. While reassuring, the confidence intervals around each estimate are wide, indicating the analysis lacks the statistical precision needed to rule out clinically meaningful differences with certainty.
What Was Studied
This study examined whether mandatory fasting before catheterization laboratory (cath lab) procedures — including percutaneous coronary intervention, transcatheter aortic valve replacement, and cardiac implantable electronic device implantation — confers measurable safety benefits over allowing patients to eat and drink normally beforehand. Current guidelines endorse preprocedural fasting, but a growing body of evidence has raised questions about whether this practice actually reduces risk or primarily causes patient discomfort without clinical justification.
How It Was Studied
Investigators performed a systematic review and meta-analysis, searching the literature for randomized controlled trials (RCTs) that directly compared fasting versus nonfasting protocols in patients undergoing cath lab procedures. Eight RCTs met inclusion criteria, together enrolling 3,068 participants: 1,544 assigned to fasting and 1,524 to nonfasting regimens. A random-effects model was applied to pool data across trials, generating odds ratios (ORs) with 95% confidence intervals for five pre-specified outcomes: hypoglycemia, aspiration pneumonia, contrast nephropathy, all-cause mortality, and cardiovascular mortality. The random-effects approach was appropriate given the expected heterogeneity in trial designs, patient populations, and procedural contexts across studies.
What Was Observed
- No significant difference in hypoglycemia risk: Nonfasting patients showed a trend toward slightly lower odds of hypoglycemia, but this did not reach statistical significance and the estimate was imprecise (OR 0.77, 95% CI 0.44–1.34), meaning the true effect could plausibly range from a meaningful reduction to a moderate increase in risk.
- No significant difference in aspiration pneumonia: Although the point estimate leaned toward a higher odds of aspiration in nonfasting patients, this finding was not statistically significant and the confidence interval was very wide (OR 1.33, 95% CI 0.38–4.72), reflecting substantial uncertainty given the rarity of this event.
- No significant difference in contrast nephropathy: The odds of contrast-induced nephropathy were numerically higher in the nonfasting group, but again the result did not reach significance and spanned a broad range (OR 1.82, 95% CI 0.88–3.75), suggesting this outcome warrants monitoring in larger trials.
- No significant differences in all-cause or cardiovascular mortality: Neither all-cause mortality (OR 1.29, 95% CI 0.51–3.28) nor cardiovascular mortality (OR 0.94, 95% CI 0.22–4.05) differed meaningfully between groups, though both estimates carry wide uncertainty intervals consistent with small event counts across trials.
Why This Matters
Preprocedural fasting is a longstanding standard that contributes to patient discomfort, dehydration, and logistical burden in busy cardiac catheterization units. This meta-analysis represents one of the most comprehensive aggregations of RCT evidence to date on the topic, and its findings align with a broader trend across procedural medicine toward liberalizing fasting requirements. For the research field, the absence of statistically significant harm signals across all five outcomes strengthens the rationale for designing larger, adequately powered trials to either confirm safety or detect previously undetectable risks, particularly for rarer endpoints like aspiration pneumonia.
How to Read This Result
The null findings across all outcomes should be interpreted cautiously: wide confidence intervals throughout — particularly for aspiration pneumonia and cardiovascular mortality — indicate that the pooled sample of approximately 3,000 participants was insufficient to detect small but potentially important differences, and larger trials are explicitly called for before conclusions can be drawn with confidence.
Limitations
The authors explicitly note that larger trials are needed to confirm the safety of nonfasting regimens, implying that the current evidence base is underpowered to detect rare adverse events. The inclusion of only eight RCTs with a total of approximately 3,000 participants limits statistical precision, as reflected in the wide confidence intervals observed for low-frequency outcomes such as aspiration pneumonia and mortality. Heterogeneity across procedural types, patient populations, and fasting definitions across the included trials may also introduce variability that the random-effects model can only partially address.